Valuation: Mabion S.A.

Market Cap 128M 32.55M 29.15M 26.89M 24.34M 45.51M 3.1B 46.25M 321M 1.62B 122M 120M 5.14B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 134M 34.15M 30.59M 28.22M 25.54M 47.76M 3.25B 48.53M 337M 1.7B 128M 125M 5.39B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
71.02%
Yield 2024 *
-
Yield 2025 -
1 day+0.63%
1 week-0.75%
Current month+1.40%
1 month+1.40%
3 months+7.41%
6 months+6.69%
Current year+14.18%
1 week 7.83
Extreme 7.83
8.17
1 month 7.64
Extreme 7.64
8.48
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
81.7
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 22/02/2021
Chairman 60 12/05/2021
Director/Board Member 53 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-0.75%-3.98%-53.50% 32.55M
+0.34%+1.12%+34.75%+61.06% 64.38B
+0.50%+3.27%+15.01%+84.68% 56.16B
+0.89%+2.34%+15.80%+107.58% 54.16B
-2.05%-3.56%+24.46%+52.08% 45.33B
+0.25%-1.86%+20.25%+98.61% 42.25B
-0.91%+0.51%+219.25%+924.22% 40.78B
+2.07%+46.29%+110.27%+94.27% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.07%+3.76%+47.00%+140.23% 39.27B
Weighted average by Cap. -0.06%+3.60%+49.61%+160.66%

Financials

2024 2025
Net sales 69.02 17.55 15.72 14.5 13.12 24.54 1.67K 24.93 173.01 874.58 65.86 64.46 2.77K 15.76 4.01 3.59 3.31 3 5.6 381.52 5.69 39.5 199.67 15.04 14.72 632.4
Net income -6.33M -1.61M -1.44M -1.33M -1.2M -2.25M -153M -2.29M -15.88M -80.26M -6.04M -5.92M -254M -62.61M -15.92M -14.26M -13.16M -11.9M -22.26M -1.52B -22.62M -157M -793M -59.75M -58.47M -2.51B
Net Debt -35.18M -8.95M -8.01M -7.39M -6.69M -12.51M -852M -12.71M -88.2M -446M -33.57M -32.86M -1.41B 6.32M 1.61M 1.44M 1.33M 1.2M 2.25M 153M 2.28M 15.83M 80.03M 6.03M 5.9M 253M
Projected Income Statement - Annual - Mabion S.A.
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
30/10/26 PLN 7.970 +0.63% 11,414
29/10/26 PLN 7.920 -0.50% 10,034
28/10/26 PLN 7.960 -0.13% 16,644
27/10/26 PLN 7.970 -0.38% 14,906
26/10/26 PLN 8.000 -0.37% 23,487

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Mabion S.A.